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Abstract
In 2014, the debate on the indication of revascularization in case of
asymptomatic carotid disease continued, while another one regard-
ing the use of surgery vs. stenting addressed some new issues regard-
ing the long-term cardiac risk of these patients. Renal arteries
interventions trials were disappointing, as neither renal denervation
nor renal artery stenting was found associated with better blood
pressure management or outcome. In contrast, in lower-extremities
artery disease, the endovascular techniques represent in 2014major
alternatives to surgery, even in distal arteries, with new insights
regarding the interest of drug-eluting balloons. Regarding the aorta,
the ESC published its first guidelines document on the entire
vessel, emphasizing on the role of every cardiologist for screening
abdominal aorta aneurysm during echocardiography. Among vascu-
lar wall biomarkers, the aorta stiffness is of increasing interest with
new data and meta-analysis confirming its ability to stratify risk,
whereas carotid intima-media thickness showed poor performances
in terms of reclassifying patients into risk categories beyond risk
scores. Regarding the veins, new data suggest the interest of
D-dimers and residual venous thrombosis to help the decision of
anti-coagulation prolongation or discontinuation after the initial
period of treatment for deep vein thrombosis.
Carotid disease
In a systematic review andmeta-analysis (56 studies) for theU.S. Pre-
ventive Services Task Force,1 the authors concluded a lack of suffi-
cient evidence to establish incremental benefit of carotid
endarterectomy (CEA), carotid stenting (CAS), or medical therapy
intensification beyond current standard medical therapy, leading to
a recommendation against screening for asymptomatic carotid
artery stenosis in general population.2 In line with this, a recent ana-
lysis of an ongoing trial3 comparingmedical therapy alone vs. CEAvs.
CAS in asymptomatic carotid stenosis looked for the clinical signifi-
cance of progression of asymptomatic carotid stenosis. No statistic-
ally significant difference in annual stroke rates can be found between
the progression- and non-progression groups, underlining the fact
that the stenosis degree is not the sole factor of incident stroke.
Further criteria are matter of active research, including ultrasound
assessment of microembolic signals or cerebral blood flow reserve,
identificationof high-risk plaque throughultrasound,MRIor positron
emission tomography, and the detection of asymptomatic brain
damage.3 Against the general trend showing safety in case of asymp-
tomatic carotid stenosis treated with current standards of medical
therapy, a recent series reported high rates of early ischaemic neuro-
logic events after ultrasound diagnosis, especially in case of .90%
stenosis, in favour of intervention.4 This study suggests that there
may be still some place for discussion regarding revascularization
of asymptomatic carotid stenosis, mainly because there might be a
subgroup of asymptomatic patients with a higher stroke risk, which
must be identified by future research.
The preferred strategy to cure carotid stenosis (either asymptom-
atic or symptomatic) is also still debated. Carotid stenting has
become increasingly popular as an alternative to CEA, with less inva-
siveness, more comfort for the patient and shorter recovery period.
Long-term safety and clinical durability of CAS compared with CEA
have been established by numerous randomized clinical trials
(RCTs), although they differ regarding their reported peri-operative
safety. In addition, significant differences in the requested operators’
experience were present. A recent publication of the Carotid Stent-
ing Trialists Collaboration highlighted the significant effect of opera-
tor’s experience on outcome.5 In 2014, the Cochrane StrokeGroup
updated their review and concluded that CAS was associated with a
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higher risk thanCEA for death and any strokewithin 30 days of treat-
ment. This statement was supported by the results from a National
Hospital Discharge Database.6 Large registries have obtained data
(only fromexpert centres of excellence) on equivalence, or the non-
inferiority, of CAS over CEA.7 The long-term (10 years) results of a
single-centre study comparing CAS with CEA with equivalent risk
of death (over 50%) and similar risk of ipsilateral stroke for both
procedures has been recently reported.8
Based on themost updated literature, the 2014 AHA/ASAGuide-
lines9 recommended CAS as an alternative to CEA for symptomatic
patients at average or low risk for complications, quite similar to the
ESC guidelines in 2011.10 For patients .70 years, CEAmay be asso-
ciatedwith improvedoutcome comparedwithCAS. Importantly, the
trials supporting these guidelines were mainly focused on mortality
and stroke. The trial providing 10 years results reported higher long-
term risk ofmyocardial infarction (MI) in case of symptomatic carotid
stenosis, especially among patients who underwent CEA, in accord-
ance with several earlier reports showing increased risk of peri-
operative MI. It is plausible that the coronary risk should also be
entered in the equation for selecting appropriate carotid revascular-
ization modality, but this requires further studies.8
Renal arteries
The CORAL trial (Table 1), the largest ever performed to assess the
benefits of angioplasty in case of renovascular disease put a definite
full stop on the extended use of this technique to hypertension
and/or limit renal failure.16 A meta-analysis adding these new data
to those of other six trials (a total of 2139 patients with atheroscler-
otic renal stenosis) confirmed the lack of improvement in any
outcome.18 At this point, even the analysis of subgroups (e.g. renal
function class, hypertension severity, stenosis degree, intra-arterial
pressure recovery, etc.) have not identified anybenefit of renal angio-
plasty overmedical treatment in any setting. Nonetheless, these data
are related to atheroscleroticdisease, and renal angioplasty shouldbe
discussed in case of fibromuscular dysplasia.
The evenmore disappointing data came from themulticentre ran-
domized single-blind Simplicity-3 trial (Table 1), comparing renal de-
nervation with a sham procedure, conducted to validate the prior
promising results in favour of major benefits to control resistant
hypertension (i.e. uncontrolled hypertension with systolic blood
pressure ≥160 mmHg despite taking ≥3 anti-hypertensive drugs
at maximally tolerated doses).17 The lack of efficacy, both in office
and ambulatory pressure change, halted the big momentum of
ongoing (or planned) trials. New technology, pathophysiology
insights, and a better selection of patients are potential keys for
future success.
Lower-extremities artery disease
TheGlobal BurdenDisease estimated increased LEAD-relateddeath
between 1990 and 2010 (Figure 1).19 In theUSA, the incidence of CLI
was estimated at 0.35% per year but one half of patients declaredCLI
without previous diagnosis of LEAD.20
Two studies identified elevated cardiac biomarkers as a tool for
risk stratification in patients with LEAD, as they were tightly asso-
ciated with worse prognosis. In patients undergoing endovascular
revascularization, pre-procedural cardiac troponin-T (cTnT) levels
.0.01 ng/mL were independently associated with 1-year all-cause
mortality (HR ¼ 8.1) and amputation (HR ¼ 3.7).21 In claudicants,
high cTnT was associated with increased risk of 7-year all-cause
and cardiovascular (CV) death.22 The clinical relevance of the use
of cTnT for risk stratification in LEAD needs further investigation.
The benefits of statins in preventing peripheral outcomes in LEAD
patients (218% at 4 years)werehighlighted in theREACHregistry.23
A recent meta-analysis confirmed the benefits of exercise training
on walking distances.24 Current research is focused on home-based
exercise, with favourable effects in in terms of walking distance and
vascular function.25,26
In the IRONIC trial (158patients), qualityof life improved in caseof
revascularization ( vs. medical therapy) despite trivial amelioration of
total walking distance, reopening the debate of revascularization in
claudicants.13
Initial studies comparing drug-eluting balloons (DEBs) with percu-
taneous transluminal angioplasty (PTA) suggested that DEB may
reduce restenosis and reintervention rates and improve wound
healing/limb preservation in CLI patients. Two RCTs on DEB have
been published in this setting in 2014.11,12 The LEVANT-I trial rando-
mized 101 Rutherford classes 2–5 femoro-popliteal lesions to
Lutonix DEB or PTA, after stratification by intention to stent the
lesion.12 At 6 months, DEB yielded lower late lumen loss (LLL)
(Table 1). The IN.PACT-DEEP randomized 358 patients with CLI 2
: 1 to DEB or PTA. Despite significantly longer lesions and deeper
ulcers in the PTA arm, unexpectedly neither the clinically driven
target lesion revascularization (TLR) nor the LLL were significantly
better in the DEB arm at 1 year (Table 1).11 While the study met its
non-inferiority hypothesis regarding the primary safety endpoint,
there was a trend towards increased major amputations (8.8 vs.
3.6%; P ¼ 0.080) in theDEB arm.These results should be interpreted
as device-specific and should not preclude further research, which
should be systematically associated with standardized wound care.
Most recently, the IN.PACTSFA I trial was presented; 331 patients
with femoro-popliteal lesions in Rutherford classes 2–4were rando-
mized 2 : 1 to DEB or PTA.14 At 12 months, the DEB group showed
better primary patency (Table 1), clinically driven TLR (2.4 vs. 20.6%),
and MACE rate (6.3 vs. 24.3%) (P, 0.001 for all), setting DEB as a
primary therapy for atherosclerotic lesions of the superficial
femoral artery. This is the first trial showing superiority of DEB
over PTA based on clinical endpoints. Balloon materials and
coating technologies affect substantially the ability of DEB to
deliver therapeutic paclitaxel regimens into the vessel wall. This,
along with patients and lesions selection may explain the variability
of results obtained, requiring therefore further trials to refine the
best techniques and indications.
Abdominal aorta aneurysm
TheESCguidelineson themanagementof thewhole aortawerepub-
lished in 2014.27 They emphasized on the opportunistic screening of
abdominal aorta aneurysm (AAA) during echocardiography in men
.65 years (Class IIa, Level B), based on a French nationwide study
reporting a 5.4% prevalence, at the median cost of 1.7 min to
screen AAA.28 These guidelines emphasized on the high level of
CV risk in these patients and the importance of prevention and
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Table 1 Summary of major randomized trials or meta-analyses in peripheral intervention in 2014
Study Aim Type Challenger Reference No. of
participants:
total
(challenger/
comparator)
Setting
(indication)
Primary endpoint Main objective achieved?
Carotid arteries
Meta-analysis for the
US Preventive
Services Task
Force1
To assess benefits of
screening and
treating CS
(asymptomatic)
Meta-analysis Screening + revasc. if
needed
No screening 78 Reports/56
studies
Population Stroke or TIA No sufficient evidence
Lower-extremities arteries
IN.PACT-DEEP11 To compare DEB vs.
PTA for BTK
lesions
Open DEB PTA 358 (239/119) CLI Efficacy: clinically driven
TLRandLLL at 1 year;
safety: composite of
death, major
amputation, and TLR
Efficacy No: TLR 9.2 vs.
13.1% (P ¼ 0.29); LLL
0.61+ 0.78 mm vs.
0.62+ 0.78 mm
(P ¼ 0.95); safety yes: 17.7
vs. 15.8% (P ¼ 0.02a)
LEVANT-I12 CompareDEBvs. PTA
in fem-pop lesions
Open DEB (+ stenting) PTA (+ stenting) 101 (49/52) Rutherford
classes 2–5
fem-pop
lesions
Late lumen loss at 6
months
Yes: 58% lower LLL
(P ¼ 0.016)
IRONIC13 Benefits of
revascularization
on quality of life
Open Revascularization
(surgical or
endovascular)
Non-supervised
training advice
158 (79/79) Unselected
patients with
claudication
Health-related quality of
life after 1 year
Yes: improved quality of life
(P, 0.01)
IN.PACT SFA I14 DEB vs. PTA for
fem-pop lesions
Open DEB PTA 331 (220/111) Rutherford
classes 2–4
fem-pop
lesions
Efficacy: primary
patency at 1 year;
safety: freedom
MAEb
Efficacy yes: primary patency
82.2 vs. 52.4%
(P, 0.001); safety yes:
MAEb 6.3% vs. 24.3%
(P, 0.001)
Abdominal aorta
IMPROVE15 EVARvs. open surgery
in ruptured AAA
Open EVAR Open surgery 613 (316/297) Patients referred
for ruptured
AAA
30-day mortality No: 30-day death EVAR: 35.4
vs. 37.4% (surgery),
P ¼ 0.62
Renal arteries
CORAL16 Benefits of renal
artery stenting in
renovascular HTN
Open Renal artery stenting Medical therapy 933 (459/472) Renal artery
stenosis with
either HTN or
CKD
Death, nonfatal MI,
stroke, renal
function, and hosp.
for CHF.
No: HR ¼ 0.94 (P ¼ 0.58)
SIMPLICITY-317 Benefits of renal
denervation in
resistant HTN
blinded Denervation
(+medical therapy)
Sham (+medical
therapy)
535 (364/171) Resistant HTN
(≥160 mmHg
with ≥3 drugs)
6-months office SBP
change
No:22.39 mmHg difference
(P ¼ 0.25)
AAA, abdominal aorta aneurysm; CS, carotid artery stenosis; DEB, drug-eluting balloon; EVAR, endovascular aortic repair; Fem-pop, femoro-popliteal; HTN, hypertension; LLL, late lumen loss; PTA, percutaneous transluminal angioplasty; SBP,
systolic blood pressure; TIA, transient ischaemic attack.
aFor non-inferiority.
bCombining death, clinically driven TVR, major amputation, and thrombosis.
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medical therapy beyond aortic interventions.27Apost hoc analysis of a
Dutch randomized trial comparing surgery vs. endovascular aortic
repair (EVAR) for AAA showed a significant reduction of long-term
total- (by 50%) and CV mortality (by 60%) in case of preoperative
statins,29 in line with data from a large national database (.20 000
interventions), which showed that .50% of these patients were re-
grettably not under statins.30 In turn, anti-coagulation, often neces-
sary for cardiac indications in patients undergoing EVAR, could
increase the risk of endoleaks31,32 and reintervention,31 suggesting
closer surveillance.
In most centres, patients with AAAs are usually treated endovas-
cular (EVAR), if the anatomy is suitable. The ESC guidelines put at a
same level of performance open surgery and endovascular therapy
(EVAR).27 Clinical evidence based on several RCTs indicates that
EVAR is associated with superior peri-operative outcomes and
similar long-termoutcomes if comparedwith open surgery, although
requiring more often re-intervention. Nevertheless, the mortality
rates reported in these trials is lower than those in registries,
outside the restrictions of RCTs.33 Since these RCTs, stent-graft
technology has been further developed by profile down-sizing, fix-
ation, and sealing optimization, the use of low porosity fabrics,
improved imaging techniques and better intervention planning. For
these reasons, the ESCGuidelines recommended that the indication
for EVAR be decided on an individual basis, according to anatomy,
pathology, comorbidity, and anticipated durability.27
In the past few years, fenestrated and branched stent-graft systems
have increasingly been used to treat anatomically challenging aneur-
ysms. At the same time, chimney techniques have been used to
extend landing zones for EVAR. The results of both techniques dem-
onstrate that the procedure can be implemented with a high degree
of success. On the other hand, there is concern about the major
adverse events, including side-branch patency and endoleak.34,35
Ongoing studies and technological refinement of stent grafts will
hopefully continue to broaden the utilization of EVAR.
There is clinical equipoise between open surgical repair and EVAR
for patients with a ruptured AAA (rAAA). A systematic review and
meta-analysis and an RCT comparing treatment strategy showed
that EVAR is not inferior to open repair in patients with an rAAA.
This supports theuseof EVAR in suitablepatients andORas a reason-
able alternative.15,36
Vascular wall biomarkers
Peripheral vascular wall biomarkers show great potential in improv-
ing risk prediction beyond scores based on risk factors. An abnor-
mal value of a biomarker would imply closer follow-up and earlier
or even intensified preventive therapies. In a recent meta-analysis of
17 635 individual data, a 1 SD increase in carotid-femoral pulse
wave velocity (cfPWV) increases CV events, CV mortality and
total mortality by 30, 28, and 17%, respectively.37 Most importantly,
this arterial stiffness biomarker fulfils a stringent criterion for quali-
fication as surrogate clinical endpoint: it improves overall 10-year
risk classification for intermediate risk subjects by 13%.37 In patients
with erectile dysfunction, a prognostic marker of generalized arter-
ial disease and CV events, cfPWV improves risk prediction and re-
classifies 28% of patients to higher or lower risk category.38 In
contrast, cIMT showed a mediocre improvement (5.6%) in net re-
classification index in intermediate risk patients with hypertension,
currently tempering the expectations for this biomarker.39 In an
attempt to “map” arterial stiffness along the arterial tree, the Hoorn
Figure1 Mean death rates (per 100 000) related to lower-extremities artery disease in the 21 global regions, 1990 and 2010. TheGlobal Burden
Disease project. Adapted from Sampson et al.19
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study40 showed that local carotid and femoral arterial stiffness indices
predicted, independently from each other and from cfPWV, all-cause
mortality and CV events. Central (aortic, carotid) pressures are lower
than peripheral (brachial) pressures and they may have a better pre-
dictive ability. Difference between central and peripheral pressures
is higher in younger ages, in males, and with increasing levels of
blood glucose, while smoking and dyslipidaemia decrease this differ-
ence.41 In an important step towards clinical implementation, refer-
ence values for central pressures were determined in a general
healthy population and according to CV risk factors (Figure 2).41
Figure2 Tridimensional bar graphs representing amplification (peripheral—central systolic blood pressures represented bymedians) accord-
ing to sex (females up, males bottom), age, and blood pressure categories. Some categories are not represented because there were ,50
observations.41
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Venous thrombosis
In occasion of the first World Thrombosis Day (13 October 2014),
an article by Raskob et al. showed that VT has a similar impact on
CV mortality and morbidity as arterial thrombosis.42 Across a wide
range of low,middle, and high income countries, annual VT incidence
ranges from 0.75 to 2.69 per 1000 individuals, up to 2–7 per 1000
among those aged .70, which represents a major global disease
burden. Its prevention is therefore an important goal in CV preven-
tion. The INSPIRE trial provides evidence of a 40% VT recurrence
reduction under aspirin, suggesting a role for this drug in patients
unfit for oral anti-coagulants (which remain the mainstream treat-
ment).43 Indeed, direct oral anti-coagulants are changing VT treat-
ment paradigms showing a safer profile with similar efficacy as
anti-vitamin K.44 Likely, a growing number of VT patients will
benefit from these drugs as their refinement is pursuing.
Identification of patients at low risk of VT recurrence after an initial
episode is important to withheld unnecessary and potentially harmful
anti-coagulation. The DULCIS study showed that persistently normal
D-dimer tests allow safe anti-coagulation discontinuation in.50% of
patients after a single VT episode (idiopathic or secondary to
weak factors).45TheCancer-DACUSstudy46assessedthe importance
of residual VT, assessed by ultrasound, 6 months after low-molecular-
weight heparin treatment in patients with cancer-associated DVT.
Results showed that in the absence of residual VT, anti-coagulation
discontinuation is safe while its continuation in case of residual VT,
up to 1 year, does not appear to be beneficial. Early thrombolysis has
been shown to increase vein patency and reduce the incidence of
post thrombotic syndrome offering potential advantages for selected
patients.47 Further studieson long-termclinicaloutcomes, comparative
procedures, and cost analysis of interventional procedures as well as
risk stratification of patients with VT disease are necessary.
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